Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The project is designed to test new biomarkers that are more sensitive than the current standard in detecting injury to the proximal kidney tubule and will establish better criteria for when kidney safety concerns may halt further testing of a drug in humans.
| Condition |
|---|
|
Cystic Fibrosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis |
urine and blood
| Estimated Enrollment: | 150 |
| Study Start Date: | February 2012 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Patients with cystic fibrosis treated with aminoglycosides |
| Patients with cystic fibrosis not treated with aminoglycosides |
Detailed Description:
The goal of this clinical study is to advance the acceptance of new biomarkers designed to detect drug-induced kidney injury in clinical trials.
The Kidney Safety Project is being conducted at four major medical centers:
- University of Southern California
- University of Minnesota
- MD Anderson Cancer Center
- Dana-Farber Cancer Institute.
Blood and urine samples will be collected from patients undergoing treatment with either cisplatin or aminoglycosides, which are two different drugs known to cause injuries to the proximal tubule of the kidney. Aminoglycosides are a common antibiotic drug taken by patients with cystic fibrosis. Cisplatin is a common chemotherapy drug taken by patients with head and neck cancer.
The Aminoglycoside Study of the Kidney Safety Project is being conducted at the University of Southern California and the University of Minnesota and aims to evaluate aminoglycoside induced acute kidney injury in patients with cystic fibrosis.
The companion study, the Cisplatin Study of the Kidney Safety Project, is being conducted at the MD Anderson Cancer Center and the Dana-Farber Cancer Institute and aims to evaluate cisplatin induced acute kidney injury in patients with head and neck cancer.
The data from the Kidney Safety Project, from both the Aminoglycoside Study and the Cisplatin Study, will be combined for determination of the best biomarkers for predicting drug-induced acute kidney injury.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
cystic fibrosis patients
Inclusion criteria:
- Males and females ≥ 18 years of age.
Documentation of CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- Sweat chloride greater than or equal to 60 mEq/L by quantitative pilocarpine iontophoresis test.
- Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; or
- Abnormal nasal potential difference.
- Hospitalized and initiated on systemic antibiotic therapy for treatment of an acute pulmonary exacerbation.
- Willingness and ability to comply with study procedures and study restrictions.
- Ability to provide written informed consent.
Exclusion criteria:
- Chronic kidney disease defined by microalbuminuria (> 30 mcg/mg creatinine) or eGFR < 60 mL/min/1.73m2.
- Receiving medications known to alter the tubular secretion of creatinine (e.g. trimethoprim, cimetidine).
- Hospitalized for treatment of an acute pulmonary exacerbation or received intravenous aminoglycoside antibiotics within 3-months of study entry.
Contacts and Locations| Contact: Irene Nunes, OD, PhD | (732) 594-1137 | irene_nunes@merck.com |
| Contact: Jessica Ratay, MS | (301) 435-4038 | jratay@fnih.org |
| United States, California | |
| University of Southern California | Recruiting |
| Los Angeles, California, United States, 90033 | |
| Contact: Research Coordinator1 | |
| Contact: Research Coordinator2 | |
| Principal Investigator: Paul Beringer, PharmD | |
| United States, Minnesota | |
| University of Minnesota - Cystic Fibrosis Center | Recruiting |
| Minneapolis, Minnesota, United States, 55455 | |
| Contact: Research Coordinator1 | |
| Contact: Research Coordinator2 | |
| Principal Investigator: Joanne Billings, MD | |
| Principal Investigator: | Paul Beringer, PharmD | University of Southern California |
| Principal Investigator: | Joanne Billings, MD | University of Minnesota - Clinical and Translational Science Institute |
More Information
No publications provided
| Responsible Party: | Foundation for the National Institutes of Health |
| ClinicalTrials.gov Identifier: | NCT01543620 History of Changes |
| Other Study ID Numbers: | Kidney Safety - Aminoglycoside |
| Study First Received: | February 28, 2012 |
| Last Updated: | March 8, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Foundation for the National Institutes of Health:
|
kidney safety biomarkers serum creatinine BUN cystic fibrosis head and neck cancer |
renal injury drug induced acute kidney injury aminoglycoside cisplatin nephrotoxicity biomarker qualification |
Additional relevant MeSH terms:
|
Cystic Fibrosis Fibrosis Pancreatic Diseases Digestive System Diseases Lung Diseases |
Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 19, 2013